jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vividion Therapeutics, Inc.

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Appoints Frank Poschen to Board of Directors
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics to Expand with New Global Research and Development Center
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2023’ Award Winner by the San Diego Union-Tribune
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Names Shawn Rose as Chief Development Officer
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Recognized as a San Diego area ‘Top Workplaces 2022’ Award Winner by the San Diego Union-Tribune
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Announces Formation of Scientific Advisory Board
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Appoints Christine Siu to Board of Directors
From Vividion Therapeutics, Inc.
Via Business Wire
Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
From Vividion Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News